Indivior PLC





Market Closed - London S.E. 11:35:29 2024-06-17 EDT 5-day change 1st Jan Change
1,281 GBX -2.81% Intraday chart for Indivior PLC -2.51% +8.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder CI
Indivior Confirms FY24 Outlook MT
Transcript : Indivior PLC - Shareholder/Analyst Call
Indivior reconfirms 2024 outlook amid NY-listing decision AN
Indivior plc Reaffirms Revenue Guidance for the Year 2024 CI
The latest transactions by star managers Our Logo
Indivior PLC Announces Board Committee Changes CI
Deutsche Bank Kicks Off Indivior Coverage at Buy MT
Jefferies cuts AJ Bell; Deutsche likes ConvaTec AN
Transcript : Indivior PLC, Q1 2024 Earnings Call, Apr 25, 2024
London-listed Indivior Confirms Plan for Primary Listing in US MT
Indivior Seeks Shareholder Nod for Listing in the United States CI
UK-listed drugmaker Indivior seeks shareholder nod for US listing RE
Indivior shares down despite profit boost on planned shift to New York AN
Indivior Reports Higher Q1 Net Income, Net Revenue MT
Tranche Update on Indivior PLC's Equity Buyback Plan announced on November 17, 2023. CI
Indivior plc Reconfirms Earnings Guidance for 2024 CI
Indivior PLC Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Craig-Hallum Starts Indivior With Buy Rating, $37 Price Target MT
C4X Discovery seeks AIM delisting but half-year revenue skyrockets AN
Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024 CI
Indivior CCO Richard Simkin sells GBP1 million in shares AN
UBS cuts abrdn price target but ups Darktrace's AN
Indivior Says Opvee Shows Drug Reverses Opioid-Induced Respiratory Depression Faster Than Naloxone MT
Indivior PLC Announces Publication Demonstrating that OPVEE® Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone CI
Chart Indivior PLC
More charts
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
16.25 USD
Average target price
30.86 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. INDV Stock
  4. News Indivior PLC
  5. London-listed Indivior Confirms Plan for Primary Listing in US